environment, as it does when attached to a substrate. The material will be valuable only if it can perform reliably when put to work.
Graphene stands out from other materials for its combination of superlative properties. In the right application, it could have an enormous impact. For example, although graphene does not perform well in digital electronics, there is much interest in using it to make high-frequency transistors for analogue applications -where it could be truly useful in wireless communication.
Another important, if low-profile, role for graphene could be as a passive layer for heat management in electronic devices. Such targeting of graphene's potential will be vital to its success.
A few carefully chosen driver applications, although possibly not as obvious or exciting as some of the uses currently flagged, would give research on the material a better chance of holding on to wide interest in the long term -especially from funding agencies. Overnight success takes time to build. ■
The long game
Graphene is not a miracle material, just a very promising one. It will take restraint and sustained interest to deliver its potential.
I
s it possible for a field of science to move too fast? Perhaps. Those who work on the form of carbon known as graphene have seen it rocket from the next big thing to a miracle material in less time than it can take for a research paper to be accepted and published. Yet although the hunt is on for applications that can exploit graphene's remarkable properties, the work necessary to find out how it could best be harnessed remains incomplete. This is one reason why many scientists who attended a meeting on the subject earlier this month were cautious about raising expectations too high. 'Graphene: The Road to Applications' was held in Cambridge, Massachusetts, on 11-13 May, and was hosted by Nature Publishing Group.
As with most 'overnight' success stories, the field of graphene research actually had a very slow start. Physicists have long been fascinated by this one-atom-thick planar crystal of carbon atoms, but until a few years ago most considered it a hypothetical system, useful for studying fundamental properties of matter but not able to exist in free form. It took a steady build-up of theoretical work and pioneering experiments over several decades before the research storm broke when it became possible to isolate graphene sheets in a laboratory.
The material certainly has an impressive set of properties. And there is no denying its tantalizing promise. As a thin membraneflexible, strong and impermeable -graphene is an attractive platform on which to build devices. Add to that its high electron mobility and excellent optical and thermal properties, and the potential for applications seems endless. But the key word here is potential. The reality is that for many of graphene's widely promoted applications, it currently performs no better than existing materials and conventional approaches. For example, graphene performs relatively poorly as a transparent conductor in conventional displays, touch screens and photovoltaic cells. Neither is it a serious contender to replace silicon in standard electronics, because it does not work well as a digital switch, the essential function of a silicon transistor.
This should not necessarily be discouraging; the field is still very young. Those who talk up the potential of graphene's applications should remember that it typically takes any technology some 20 years to emerge from the lab and be commercialized -and even then it can succeed only with sustained effort and interest from researchers, industry and funding agencies (see Nature 469, 14-16; 2011) .
It is crucial to identify and acknowledge practical hurdles -and when it comes to fabricating and designing graphene devices, there are many. As was stressed many times at the Cambridge meeting, the single biggest obstacle is the lack of a way to reliably produce high-quality graphene sheets in large quantities. The quality and structure of the sheets can differ from batch to batch, which can make devices behave inconsistently.
Furthermore, although the pristine form of graphene has high electron mobility, meaning that devices based on it have the potential to run at high speeds, this changes dramatically when it interacts with its "It typically takes any technology some 20 years to emerge from the lab and be commercialized." Wegman has blamed a graduate student for the plagiarism. Daniel Walsch, spokesperson for George Mason University, says that an internal review of the matter began in the autumn. He cannot estimate when that review will be complete, and, until it is, he says, the university regards it as a "personnel matter" and will not comment further. He adds that the review is still in the "inquiry" phase to ascertain whether a full investigation should be held. "Whether it is fast or slow is not as important as it being thorough and fair, " says Walsch.
The fact that 14 months have passed since Bradley's complaint without it being resolved is disheartening but not unusual. An examination of George Mason University's misconduct policies suggests that investigations should be resolved within a year of the initial complaint, including time for an appeal by the faculty member in question. According to the university's own timeline, the initial inquiry should have been complete within 12 weeks of the initial complaint -in May 2010. But there are loopholes galore for extensions, and, like many universities, George Mason seems content to drag its feet.
Long misconduct investigations do not serve anyone, except perhaps university public-relations departments that might hope every one will have forgotten about a case by the time it wraps up. But in cases such as Wegman's, in which the work in question has been cited in policy debates, there is good reason for haste. Policy informed by rotten research is likely to have its own soft spots. Those who have been wronged deserve resolution of the matter. And one can hardly suppose that those who have been wrongfully accused enjoy living under a cloud for months.
So, what incentives do universities have to pick up the pace? Agencies such as the US Office of Research Integrity and ethics offices at funding bodies should take universities to task for slow investigations and demand adherence to the schedules listed in university policies. However, the agencies themselves haven't exactly been models of swift justice.
The most recent annual report from the Office of Research Integrity -for 2008 -reported that the cases closed in that year spent a mean of 14.1 months at the agency. Perhaps it should fall to accreditation agencies to push for speedy investigations. Tom Benberg, vice-president of the Commission on Colleges of the Southern Association of Colleges and Schools -the agency that accredits George Mason University -says that his agency might investigate if the university repeatedly ignored its own policies on the timing of misconduct inquiries. To get the ball rolling, he says, someone would have to file a well-documented complaint.
Even if funding and accreditation agencies fail to apply pressure, universities should take the initiative to move investigations along as speedily as possible while allowing time for due process. Once an investigation is complete, the institution should be as transparent as it can about what happened. Especially when public funds are involved, or at public universities, the taxpayer has a right to know what happened when papers are retracted -even if the faculty member in question is eventually exonerated. This tidies the scientific record, clears the air and kicks the legs out from under any conspiracy theories. Over to you, George Mason University. 
Modern heroes
The great achievements of vaccines are not consigned to the past. I t is easy to see the heroic age of vaccines as one that ended decades ago. The Salk polio vaccine, after all, which swiftly and visibly transformed the disease into a distant memory in the developed world, was introduced in 1955. And the smallpox eradication campaign led by the World Health Organization had, by the late 1970s, reduced the virus from a killer of millions of people a year to a prisoner of biosafety labs. These were monumental feats, but the best could be still to come.
This week Nature explores the undiminished promise of vaccines, and the factors that threaten it -complacency, funding shortages and the unease that vaccines provoke in so many people.
Worldwide, up to one-third of all deaths of children under five result from diarrhoea and pneumonia. In the past ten years or so, vaccines against the microorganisms that cause many of these cases have become a standard part of the childhood regimen in the developed world. If they could be made available worldwide, the lives of hundreds of thousands of children could be saved each year.
Research efforts are adding to the promise. Together, AIDS, malaria and tuberculosis kill more people each year than smallpox did when the global campaign to eradicate it began in 1967. The search for vaccines for all three diseases has been long and frustrating, but a Perspective on page 463 describes how new technologies are reviving it.
There is no room for complacency. The global campaign to eradicate polio made stunning progress from 1988 to the end of the twentieth century, reducing worldwide incidence by 99%. But the disease continues to smoulder in Pakistan, India, Afghanistan and Nigeria, where vaccinators have struggled with turmoil and corruption, high transmission rates and suspicion about the vaccine itself (see pages 427 and 446). Similarly, a long vaccination campaign against measles has reduced the global death toll from more than 2.5 million a year in 1980 to fewer than 200,000 today. But vaccination rates are still below 80% in much of Africa and India, and funds pledged to the global measles initiative have fallen. Some people think that the disease is poised to surge again in the developing world (see page 434). Europe has already seen outbreaks, in part because vaccination rates dipped after the combined measles, mumps and rubella (MMR) vaccine was falsely linked to autism. Vaccines can become victims of their own success. In the developed world, for example, vaccination has already reduced measles to a rarity, which makes an 'informed' choice to shun the vaccine seem risk free. Even doctors and nurses can fall prey to this reasoning. They have a disproportionate influence over whether parents vaccinate their children, and when they lose sight of the overwhelming ratio of benefit to risk for most vaccines, they can amplify public fears (see page 443). Back in the 1950s, '60s, and '70s, when vaccines offered protection against clear and present menaces, it was easier to accept their small risk of harm.
Designing a cheap, effective vaccine against the more complex major killers of today is a harder task, and people everywhere are quicker to question the official line, on vaccines as on everything else. But the promise for vaccines to transform global health is as bright as ever, and funders and public-health experts must continue their heroic support for research, global vaccination efforts and communication strategies to win over the doubters. ■
